Qualigen Therapeutics (QLGN) to Release Quarterly Earnings on Tuesday

Qualigen Therapeutics (NASDAQ:QLGN) is expected to be releasing its results after the market closes on Tuesday, August 18th. Analysts expect Qualigen Therapeutics to post earnings of ($70.00) per share and revenue of $1.20 million for the quarter.

Qualigen Therapeutics Trading Down 0.4%

Qualigen Therapeutics stock opened at $0.82 on Tuesday. The company has a fifty day simple moving average of $1.06 and a 200-day simple moving average of $1.27. The stock has a market cap of $1.39 million, a P/E ratio of -0.11 and a beta of 0.24. Qualigen Therapeutics has a 12-month low of $1.61 and a 12-month high of $8.81.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.

Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories.